Trials / Terminated
TerminatedNCT04111445
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
First-in-human (FIH), Open-Label, Phase I (Dose Escalation) Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Adagene Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADG116 | IV infusion at Day 1 of each cycle |
Timeline
- Start date
- 2019-08-29
- Primary completion
- 2021-04-27
- Completion
- 2021-04-27
- First posted
- 2019-10-01
- Last updated
- 2021-09-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04111445. Inclusion in this directory is not an endorsement.